Q3 2025 Twist Bioscience Corp Earnings Call Transcript
Key Points
- Twist Bioscience Corp (TWST) reported record revenue of $96.1 million for the third quarter of fiscal 2025, marking an 18% increase year-over-year.
- The company's gross margin improved significantly to 53.4%, up from 43.3% in the same quarter of fiscal 2024.
- Revenue from the Next-Generation Sequencing (NGS) segment increased by 27% year-over-year, driven by strong demand from commercial diagnostic tests and smaller accounts.
- Twist Bioscience Corp (TWST) added hundreds of net new customers, expanding its reach in the academic market for synthetic biology products and NGS tools.
- The company is on track to achieve adjusted EBITDA breakeven, with a significant improvement in adjusted EBITDA loss by approximately $14 million compared to the third quarter of fiscal 2024.
- The Synbio segment experienced a growth of only 7% year-over-year, partly due to a tough comparison with a large order from the previous year that did not recur.
- Revenue from the Biopharma Services segment grew by only 10% year-over-year, indicating slower growth compared to other segments.
- The company anticipates a $5 million revenue normalization in Q4 due to a key account transitioning from validation to commercial deployment, which may impact short-term revenue.
- APAC revenue decreased to $5.9 million in the third quarter, down from $6.5 million in the same period of fiscal 2024, with China contributing only 1.5% of total revenue.
- Operating expenses, excluding cost of revenues, were approximately $81.4 million, showing a slight increase compared to the same period in 2024, which could impact profitability.
Ladies and gentlemen, thank you for standing by. Welcome to Twist Bioscience's 2025 third-quarter financial results conference call. (Operator Instructions) Please be advised that today's conference is being recorded.
I would like now to turn the conference over to Angela Bitting, Senior Vice President of Corporate Affairs. Please go ahead.
Thank you, operator. Good morning, everyone. I would like to thank you for joining us for Twist Bioscience's conference call to review our fiscal 2025 third-quarter financial results and business progress. We issued our financial results press release before the market, and it is available at our website at www.twistbioscience.com.
With me on the call today are Dr. Emily Leproust, CEO and Co-Founder of Twist; Adam Laponis, CFO of Twist; and Dr. Patrick Finn, President and COO of Twist. Today, we will discuss our
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
